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One approach to identifying cancer-specific vulnera-
bilities and therapeutic targets is to profile genetic
dependencies in cancer cell lines. Here, we describe
data from a series of siRNA screens that identify the
kinase genetic dependencies in 117 cancer cell lines
from ten cancer types. By integrating the siRNA
screen data with molecular profiling data, including
exome sequencing data, we show how vulnerabil-
ities/genetic dependencies that are associated with
mutations in specific cancer driver genes can be iden-
tified.By integrating additional datasets into this anal-
ysis, including protein-protein interaction data, we
also demonstrate that the genetic dependencies
associatedwithmany cancer driver genes formdense
connections on functional interaction networks. We
demonstrate the utility of this resource by using it to
predict the drug sensitivity of genetically or histologi-
cally defined subsets of tumor cell lines, including an
increased sensitivity of osteosarcoma cell lines to
FGFR inhibitors and SMAD4 mutant tumor cells to
mitotic inhibitors.
INTRODUCTION
The phenotypic and genetic changes that occur during tumori-
genesis alter the set of genes upon which cells are dependent.
The best known example of this phenomenon of ‘‘genetic de-
pendency’’ is oncogene addiction where tumor cells become
dependent upon the activity of a single oncogene, which
when inhibited leads to cancer cell death. Alternatively, tumor
cells can become addicted to the activity of genes other than2490 Cell Reports 14, 2490–2501, March 15, 2016 ª2016 The Authoroncogenes, effects known as non-oncogene addictions (Luo
et al., 2009), induced essential effects (Tischler et al., 2008),
or synthetic lethal interactions (Kaelin, 2005). From a clinical
perspective, identifying genetic dependencies in tumor cells
could illuminate vulnerabilities that might be translated into
therapeutic approaches to treat the disease. Examples of this
approach include the development of drugs that target onco-
gene addiction effects, such as imatinib in the case of ABL
addiction, and therapeutic approaches that exploit synthetic
lethal effects, such as PARP inhibitors for BRCA-deficient
cancers (Lord et al., 2015).
A number of groups have used high-throughput screening ap-
proaches such as RNAi or small molecule sensitivity screens to
systematically identify genetic dependencies in tumor cell lines
(Barretina et al., 2012; Brough et al., 2011; Cowley et al., 2014;
Garnett et al., 2012; Koh et al., 2012). A particular focus has
been in dissecting genetic dependencies that involve kinases
(Brough et al., 2011; Grueneberg et al., 2008), as these enzymes
play key roles in a number of oncogenic processes (Greenman
et al., 2007) and are pharmacologically tractable (Sakharkar
and Sakharkar, 2007; Workman and Al-Lazikani, 2013; Zhang
et al., 2009). Previously, we used high-throughput short inter-
fering (si)RNA screening to identify the kinase dependencies in
a panel of 20 breast cancer derived cell lines (Brough et al.,
2011). Here, we describe as a resource an expansion of this
approach, namely parallel siRNA screens targeting 714 genes
in 117 genetically and histologically diverse tumor cell lines.
Building on our previous work (Brough et al., 2011), we extend
our analytical approach to describe how this data set may be
used as a hypothesis-generating tool for identifying candidate
therapeutic targets associated with specific tumor histotypes
or mutations in cancer driver genes. We also illustrate how, by
integrating this functional data with orthogonal data sources
such as protein-protein interaction data sets, these genetic de-
pendencies might be dissected mechanistically.s
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A Figure 1. Screening Overview
(A) Schematic of siRNA screening, data process-
ing, and genomic data integration.
(B) Piechart illustrating histotypes for 117 cell lines
that passed QC (CNS).
(C) Frequency plot depicting the number of cell
lines in which each kinase siRNA caused a signif-
icant growth defect (Z% 2).
(D) Clustered heatmap summarizing the KGDs of
117 cell lines. The average linkage hierarchical
clustering was used with Pearson’s correlation as
the similarity metric. Only the 20% most variable
siRNA Z scores were used for the calculation
of correlations. The histotype of each cell line
is indicated by the color blocks to the left of
the heatmap and corresponds to the scheme
shown in (B).RESULTS
Kinase Genetic Dependencies Identified by Parallel
siRNA Screens
We screened a panel of 136 tumor cell lines in triplicate in a plate-
arrayed format using an siRNA library designed to target 714
genes (see Experimental Procedures and Figure 1A). The genes
targeted with this library included 500 protein kinases (Manning
et al., 2002), with the remaining targets comprising metabolic
kinases (e.g., ATP-dependent 6-phosphofructokinases), lipid
kinases (e.g., PIK3C2A), as well as proteins that lack kinase
activity, but directly impact kinase signaling (e.g., the cyclin
dependent kinase inhibitor CDKN1C). Cells were reverse trans-
fectedwith siRNA and then cultured until cells reached 70%con-Cell Reports 14, 2490–2501fluency (on average 4-7 days), at which
point cell viability was assessed using
the CellTiter-Glo assay. Following data
processing and the application of quality
control filters to ensure the reproducibility
and high dynamic range of each screen
(seeSupplemental Information; Figure 1A;
Table S1A), we retained 117 high quality
screens for further analysis. The resulting
resource (Table S1B) features tumor cell
line models from ten different cancer
types (breast, ovarian, lung, osteosar-
coma, esophageal, pancreatic, head,
and neck, cervical, CNS, and endome-
trioid; Figure 1B), and includes data for
69 lines not profiled in prior large-scale
RNAi screens (Brough et al., 2011; Cow-
ley et al., 2014; Koh et al., 2012).
To allow data to be compared between
different cell lines, the viability data from
each screen were standardized by the
use of a robust Z score statistic (Table
S1B). We considered candidate kinase
genetic dependencies (KGDs) in the
data set as those where the siRNA elicited
Z < 2 effects. 76% of the kinases pro-
filed in the screening library represented KGDs in at least one tu-
mor cell model. Additionally, 53% and 26% represented KGDs
in R5 and R10 cell lines, respectively (Figure 1C and Table
S1C). On average, each tumor cell line model exhibited 51
KGDs. A set of six kinase-coding genes (PLK1, AURKA, WEE1,
CHEK1, CDK11A, and GUCY2D) represented KGDs in >70%
of the cell lines screened and four of these (PLK1, AURKA,
WEE1, and CHEK1) are known to be involved in the mitotic
cell-cycle -checkpoint.
Candidate KGDs Associated with Tumor Histotypes
Using average linkage hierarchical clustering to cluster the siRNA
Z score data (Figure 1D), we found that tumor cell lines fre-
quently clustered according to tumor histotype. For example,, March 15, 2016 ª2016 The Authors 2491
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Figure 2. Kinase Dependencies Associated with Histotypes
(A) Radar plot summarizing the KGDs associated with the osteosarcoma histotype. The concentric circles indicate the statistical significance and the depth of
color indicates the separation of Z scores between the osteosarcoma histotype and the non-osteosarcoma group of cell lines. A set of six kinases annotated as
involved in skeletal system morphogenesis in the Gene Ontology are annotated with asterisks.
(B) Heatmap of KGDs enriched in osteosarcoma cell lines are shown as a heatmap representing siRNA Z scores. The asterisks indicate kinases involved in
skeletal system morphogenesis as in (A).
(C and D) Box plots of area under curve (AUC) estimates for 58 cell lines exposed to the FGFR inhibitor AZD4547 (C) and PD173074 (D) at eight different
concentrations. FGFR1 and FGFR2-amplified cell lines are indicated with black and green circles, respectively. The non-tumor epithelial cell lines MCF10A and
MCF12A are indicated with gray arrows.
(E) Box plot of AUC estimates for a panel of cell lines exposed to the FGFR inhibitor PD173074 (Garnett et al., 2012).
In each box plot (C–E), the top and bottom of the box represents the third and first quartiles and the box band represents the median (second quartile); whiskers
extend to 1.5 times the interquartile distance from the box. See also Figures S1 and S2.themajority of ovarian cancer cell lines formed a single cluster, as
did thosemodels derived fromosteosarcomas (Figure 1D). Using
median permutation (MP) tests on theZ score data, we found 151
KGDs associated with specific histotypes at a false discovery
rate (FDR) of 0.1 (Table S1D). As expected, the number of
KGDs associated with each histotype was correlated with the
number of cell lines screened for that histotype (Spearman’s
rho = 0.82), reflecting the increased statistical power resulting
from a larger sample size. In breast cancer models, we found
an increased requirement for ERBB3 and PIK3CA, members of
the ERBB2 and PI3-kinase signaling pathways that are fre-
quently dysregulated in this cancer histology (Miller et al.,2492 Cell Reports 14, 2490–2501, March 15, 2016 ª2016 The Author2011). In contrast, models of osteosarcoma were more reliant
upon genes involved in ‘‘skeletal system morphogenesis’’,
including PDGFRA, ACVR2B, TGFBR2, DLG1, FGFR1, and
FGFR2 (Su et al., 2008) (Gene Ontology enrichment p < 0.001 af-
ter correcting for multiple hypothesis testing, Berriz et al., 2009;
Figures 2A and 2B). The FGFR1 and FGFR2 KGDs suggested
that osteosarcomamodels might be especially sensitive to small
molecule FGFR inhibitors. Testing a set of 58 tumor cell lines for
FGFR inhibitor sensitivity, we found AZD4547 (Gavine et al.,
2012) and PD173074 (Bansal et al., 2003) to be more selective
for osteosarcoma models (AZD4547, p = 7.6 3 103,
PD173074 p = 3.9 3 102; Figures 2C and 2D; Table S1E) ands
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to have minimal effects in two non-tumor epithelial models (Fig-
ure S1). This osteosarcoma selective effect was independent of
FGFR1 or FGFR2 amplification status and was also apparent
when FGFR1 or FGFR2 amplified tumor cell lines were excluded
from the analysis (AZD4572, p = 7.2 3 103 and PD173074, p =
4.33 102; Figures 2C and 2D). Furthermore, the osteosarcoma
selective nature of PD173074 was confirmed by a reanalysis of
PD173074 sensitivity data derived from 660 tumor cell lines (Gar-
nett et al., 2012) (Figure 2E; p=1.43103). Taken together, these
results suggested that FGFR inhibitors might show some utility in
osteosarcoma, but that factors in addition to FGFR1 and FGFR2
amplification might explain drug sensitivity in this setting.
We also assessed the possibility that KGDs could be identified
that were associated with specific subtypes of cancer. We, and
others, have previously used RNAi data to identify KGDs associ-
ated with distinct breast cancer subtypes (Brough et al., 2011;
Marcotte et al., 2012). To illustrate the utility of the expanded
data set described here, we used MP tests to identify KGDs
associated with the clear cell subtype of ovarian cancer (OCC).
We found three kinases (CAMK2N1, GRK2, and MAP3K9) to
be KGDs in OCCmodels, compared to other ovarian cancer his-
tologies such as serous ovarian cancer (Figure S2; Table S1F).
Candidate KGDs Associated with Driver Gene
Alterations
By integrating the siRNA data with exome sequencing (Forbes
et al., 2015) and copy number profiling data (Barretina et al.,
2012), we identified KGDs associated with mutations in each
of 200 candidate cancer driver genes (see Supplemental Infor-
mation; Table S1G). We identified 4,247 putative dependencies
associated with driver gene mutations (uncorrected MP test
p % 0.05; Table S1H). As the large number of tests performed
using these 200 driver genes prohibited correction for multiple
hypothesis testing, we focused our subsequent analysis on 21
key cancer driver genes (12 tumor suppressor genes and nine
oncogenes; Futreal et al., 2004; Vogelstein et al., 2013) (Fig-
ure 3A) mutated in at least seven tumor cell lines in our panel.
This identified 211 KGDs at an FDR of 0.5 (Table S1I) that could
form the basis for subsequent validation experiments.
This approach reconfirmed the well-established ERBB2
oncogene addiction in models of breast cancer, but also estab-
lished ERBB2 addiction/KGD in models of esophageal cancer
(Figures 3B and 3C), where ERBB2 is recurrently amplified/over-
expressed in 20% of tumors (Bang et al., 2010). This suggestedFigure 3. KGDs Associated with Cancer Driver Mutations
(A) Bar chart indicating the frequency of driver gene alterations observed in the ce
alterations were detected.
(B) Radar plot summarizing the KGDs associated with ERBB2 amplification (the
(C) Box plot showing the ERBB2 Z scores for cell lines grouped according to ER
(D) Box plots showing additional KGDs associated with ERBB2 amplification.
(E) Box plots summarizing CCND1 KGDs upon CIT.
(F) Examples of KGDs that are supported by protein-protein interactions.
(G) Examples of KGDs that are supported by kinase-substrate relationships.
(H) Examples of KGDs that are supported by gene regulatory relationships.
(I) Examples of KGDs associated with ERBB2 amplification status in esophageal c
path between the mutated driver gene and kinases.
In each box plot (C–I), the top and bottom of the box represents the third and first
extend to 1.5 times the interquartile distance from the box. See also Figures S3
2494 Cell Reports 14, 2490–2501, March 15, 2016 ª2016 The Authorthat this particular genetic dependency was relatively indepen-
dent of the underlying histotype. ERBB2 amplification was
also associated with dependency upon other members of the
ERBB2 signaling network including the ERBB2 binding partner
ERBB3 (p = 23 103), JAK2 (p = 13 102), and the downstream
effector of ERBB2, PIK3CA (p = 4 3 103; Figure 3D). We found
other KGDs associated with ERBB2 amplification, including a
strong dependency upon the stress response kinase MEK3
(MAP2K3, p = 4 3 104; Figure 3D) (De´rijard et al., 1995) and
PIP5K1A (p = 2 3 105), a kinase involved in inositol phosphate
metabolism (Loijens and Anderson, 1996).
We assessed the possibility that some KGDs associated with
cancer driver gene mutations might be private to or more pro-
found in particular histotypes. For example, BRAF p.V600E
mutant melanomas are extremely sensitive to BRAF inhibition,
whereas colorectal cancers with the same mutation show little
response (Prahallad et al., 2012). We used a similar analysis as
above to identify KGDs associated with driver gene mutations
within particular histotypes and identified 943 KGDs (Tables
S1J and S1K), compared to 211 in the prior analysis that com-
bined all histotypes. Together, these 1,154 candidate depen-
dencies could inform the design of subsequent validation
studies. As an example of this, we selected for validation one
of the KGDs associated with RB1 mutation in osteosarcoma
(Kansara et al., 2014), DYRK1A (p = 6.8 3 103; Figure S3A), a
component of the DREAM complex (Sadasivam and DeCaprio,
2013) previously identified as a protein interaction partner of
RB1 (Varjosalo et al., 2013). To confirm the dependency of
RB1 null osteosarcoma models upon DYRK1A, we selected 14
osteosarcoma models and characterized these according to
their RB1 mutation and protein expression status and estab-
lished that multiple distinct DYRK1A siRNAs could replicate
the RB1 selectivity observed in the initial screen as well as elicit-
ing DYRK1A silencing (Figure S3). These results suggest that
DYRK1A might represent a valid genetic dependency in RB1
defective osteosarcoma cells.
We also noted from our analysis of the siRNA data that some
genetic dependencies associated with cancer driver gene
mutations were observed independently in multiple histotypes.
These included KGDs associated with ERBB2 amplification in
breast and esophageal cancer models (e.g., ERBB2 p = 7.9 3
105 [breast] and p = 9.2 3 103 [esophageal] andMAP2K3 p =
3.33 102 [breast] and p = 4.43 103 [esophageal]; Figure S4A),
but also a dependency upon the microtubule associatedll line panel. The colored segments in each bar indicate the histotypes in which
scheme as per Figure 2A).
BB2 amplification status. The colors indicate cell line histotypes as in (A).
ancer models supported by kinase-substrate relationships that form a shortest
quartiles and the box band represents the median (second quartile); whiskers
and S4 and Tables S1I and S1K.
s
serine/threonine kinase MAST1 in CCND1 amplified breast
or esophageal cancer models (p = 1.1 3 102 [breast] and
p = 1.3 3 102 [esophageal]; Figure S3B). Likewise, a KGD
upon Citron Rho-interacting kinase (CIT), a regulator of cytoki-
nesis (Madaule et al., 1998) was also seen in CCND1 amplified
breast or esophageal cancer models (p = 2. 3 103 [breast],
p = 2.6 3 103 [esophageal]; Figure 3E). In both osteosarcoma
(p = 1.4 3 103) and lung cancer models (p = 3.5 3 102; Fig-
ureS1C),we identified an association betweenmutation/deletion
of CDKN2A and dependency upon the cyclin dependent kinase
gene CDK11A, which encodes a CDKN2A interacting protein
(Varjosalo et al., 2013). In total, we identified 63 kinase depen-
dencies associated with driver gene mutation status that were
observed independently in more than one histotype (Table S1K).
Integrating Data on Protein-Protein and Regulatory
Interactions Facilitates the Interpretation of Genetic
Dependencies
The set of KGDs associated with cancer driver gene alterations
can be used to frame testable hypotheses, such as ‘‘mutation
in gene A drives dependency upon a gene B.’’ However, without
further information, there are a number of potential mechanistic
explanations for each genetic dependency. In model organisms,
the problem of interpreting such dependencies has been ad-
dressed by integrating information from protein-protein (Beyer
et al., 2007) and kinase-substrate interaction databases (Fiedler
et al., 2009). To facilitate a mechanistic understanding of KGDs
and to provide additional guidance for the design of subsequent
experiments, we annotated our list of KGDs according to
whether they involved known protein-protein interactions
(Chatr-Aryamontri et al., 2015; Das and Yu, 2012), known ki-
nase-substrate relationships (Lachmann and Ma’ayan, 2009),
or known regulatory relationships (Cerami et al., 2011) between
the driver gene and the identified dependency (see Experimental
Procedures). Doing this, we found 113 KGDs involved pairs of
genes with a previously reported functional relationship between
the mutated driver gene and kinase target (Tables S1I and S1K).
For example, mutation/amplification of EGFR in lung cancer cell
lines was associated with an increased dependency upon FES
(p = 33 102; Figure 3F), previously identified as an EGFR bind-
ing partner (Jones et al., 2006). Similarly, in esophageal cancer
models, we identified a significant association betweenmutation
of the chromatin remodeling factor gene SMARCA4 and depen-
dency upon the bromodomain protein BRD4 (p = 6 3 103; Fig-
ure 3F), previously identified as a protein interaction partner of
SMARCA4 (Rahman et al., 2011). Among the dependencies
associated with a kinase-substrate interaction, we found that
mutation of STK11 (LKB1) in ovarian cancer models was associ-
ated with an increased dependency uponMARK2 (p = 23 103;
Figure 3G), an LKB1 substrate (Lizcano et al., 2004). Similarly, we
found that MYC (cMYC) amplified esophageal models had an
increased dependency upon MAPK1 (ERK-2, p = 1.2 3 102;
Figure 3G), which is known to phosphorylate and stabilize the
cMYC protein (Sears et al., 2000). We also identified a series of
dependencies between cancer driver genes and their transcrip-
tional targets, the majority of which focused upon MYC. In lung
cancermodels, we found thatMYC amplification was associated
with an increased dependency upon CDKL5 (5.6 3 103; Fig-Cellure 3H), a genewhose expression is regulated byMYC. Similarly,
in esophageal models, we found MYC amplification to be asso-
ciated with an increased dependency upon the MYC transcrip-
tional target PRKCH (Zeller et al., 2006) (p = 6.7 3 103;
Figure 3H).
For KGDs where a direct relationship between the driver gene
and the kinase was not known, we used a simple information-
flow type analysis to identify the shortest known molecular
paths between driver gene and the kinase dependency (Tables
S1I and S1K). For example, one of the strongest dependencies
identified across all histotypes was between STK11 and
SRP72 (Figure S4C). We found no evidence of a direct relation-
ship between the two genes, but found that STK11 has been
shown to regulate the expression ofMYC (Nath-Sain and Marig-
nani, 2009), which in turn has been shown to regulate SRP72
(Zeller et al., 2006), suggesting a putative path linking the driver
gene and the kinase dependency. In esophageal cancer models,
we found that ERBB2 amplification is associated with MASTL
(Voets and Wolthuis, 2010) and NEK9 (Belham et al., 2003)
KGDs (Figure 3I). We found no direct link between ERBB2 and
either of these kinases, but both are CDK1 substrates and
CDK1 itself is an ERBB2 substrate. In this instance, all members
of the path (ERBB2/CDK1/NEK9/MASTL) were identified as
ERBB2 dependencies. In total, 163 dependencies not supported
by a direct link could be reached by adding one intermediate
connection (e.g., CDK1 is an intermediate connection between
ERBB2 and NEK9).
Pathway and Network Level KGDs
Work in model organisms has shown that a genetic mutation
often results in an increased dependency on not just one gene,
but multiple genes involved in a specific pathway or complex
(Collins et al., 2007; Kelley and Ideker, 2005; Ryan et al., 2012).
To explore the utility of this concept in interpreting our KGD
data, we mapped the nominally significant KGDs (p % 0.05)
identified for each cancer driver gene across all histotypes
onto the high-confidence STRING functional interaction network
(Franceschini et al., 2013) (see Experimental Procedures). For
11 of the 21 driver genes analyzed (KRAS, ERBB2, CCND1,
PIK3CA, SMAD4, NOTCH2, ARID1A, NF1, FBXW7, MAP2K4,
and RB1), we found that the dependencies associated with
each driver gene were significantly more connected on the
STRING interaction network than would be expected by chance
(see Experimental Procedures; Figure S5; Table S1L). This sug-
gested that these 11 driver genes might induce dependencies
not just on individual genes, but on functional subnetworks.
For two of these networks, we added known protein-protein
and kinase-substrate interaction data to aid their interpretation.
In the case of the network associated with ERBB2 amplification,
this suggested that ERBB2 amplification might induce depen-
dencies on direct binding partners and substrates of ERBB2
(JAK2, ERBB3, and PIK3CA), but also a network of genes
involved in MAPK signaling (e.g., MAP2K3, MAP3K4, and
MAP3K2) and inositol phosphate metabolism (including
PIP5K1A, PIK3CA, and PIK3CD) (Figure 4A). Similarly, we found
significantly more functional interactions among the kinases
identified as dependencies associated with mutation of the tu-
mor suppressor SMAD4, a member of the TGF-b pathway thatReports 14, 2490–2501, March 15, 2016 ª2016 The Authors 2495
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Figure 4. Driver Gene KGDs and Functional Interaction Networks
(A) Functional interaction network showing interactions between ERBB2
amplification-associated KGDs. The nodes correspond to kinases that are
identified as KGDs in ERBB2 amplified cell lines. The nodes are scaled to
indicate the significance of the KGD association p value. The blue edges
correspond to experimentally determined protein-protein interactions, the
pink arrows indicate the direction of experimentally determined kinase-sub-
strate interactions, and the gray edges reflect high-confidence STRING
functional interactions. Only KGDs that interact with at least one other ERBB2
dependency are shown.
(B) Functional interaction network showing interactions among KGDs identi-
fied in SMAD4 mutated cancer cell lines. Details as for ERBB2 network in (A).
(C) Box plot showing AUC values of a panel of cell lines exposed to com-
pounds targeting microtubules (paclitaxel and epothilone B) or Aurora Kinases
(VX680) and classified into SMAD4 mutant or wild-type groups. The top and
bottom of the box represents the third and first quartiles and the box band
represents the median (second quartile); whiskers extend to 1.5 times the
interquartile distance from the box.
See also Figure S5 and Table S1L.is frequently mutated or homozygously deleted in colorectal
(Thiagalingam et al., 1996), pancreatic (Hahn et al., 1996), and
esophageal (Dulak et al., 2013) cancers (Figure 4B). The inte-
grated network we constructed from SMAD4 KGDs revealed
that AKT1 and a number of its substrates (FGR, MAP3K3,
PIKFYVE,CHEK1, andWEE1) were SMAD4mutation associated
KGDs. Consistent with this, loss of SMAD4 has been shown to
be associated with increased AKT activation in colorectal and
pancreatic tumor cell lines (Chen et al., 2014; Zhang et al.,
2014). Furthermore, a recent large-scale drug screen identified2496 Cell Reports 14, 2490–2501, March 15, 2016 ª2016 The AuthorSMAD4 as the only driver gene significantly associated with
sensitivity to A-443654, a pan-AKT inhibitor (Garnett et al.,
2012). In addition to AKT1 and its substrates, we found a densely
connected group of kinases that regulate the mitotic cell cycle in
the SMAD4 dependency network (Figure 4B), suggesting that
SMAD4 mutant tumor cell lines may have an increased sensi-
tivity to perturbation of this process. To test this hypothesis,
we analyzed a compendium of drug sensitivity profiles (Garnett
et al., 2012) and found that SMAD4 mutant cell lines have
increased sensitivity to the Aurora Kinase inhibitor VX-680 (Har-
rington et al., 2004) (p = 4 3 103; Figure 4C). Furthermore, we
found that SMAD4 mutant cell lines also exhibited an increased
sensitivity to the mitotic inhibitors paclitaxel (p = 8.33 105) and
epothilone B (p = 3 3 103; Figure 4C), suggesting a general
sensitivity to drugs that target the mitotic checkpoint.
We present the functional interaction networks for the depen-
dencies associated with each driver gene in Figure S5 and Table
S1L. In addition to aiding the interpretation of dependencies,
these subnetworks may be useful in alleviating some of
the problems associated with false-positive effects in high-
throughput genetic screens. Although there is a possibility of
any given dependency being the result of off-target siRNA ef-
fects (Jackson and Linsley, 2010), the likelihood of an entire
pathway being identified through off-target effects is likely to
be much lower.
In the examples described above, we used the siRNA data to
identify KGDs associated with defects in individual driver genes.
Although there are hundreds of reported driver genes in cancer,
some of these can be grouped into a small number of recurrently
altered pathways (Garraway and Lander, 2013). Furthermore, it is
possible that mutation in any member of such a pathway might
have similar phenotypic effects. With this in mind, we considered
whether we could identify candidate ‘‘pathway level’’ depen-
dencies by grouping tumor cell lines according to mutations in
any one of a set of driver genes belonging to the same pathway
or complex. We obtained a previously curated list of pathways
associated with driver gene mutations (Garraway and Lander,
2013) and manually updated this using literature information on
well-established pathways (e.g., homologous recombination).
For each pathway, tumor cell lines were grouped using a logical
OR argument, i.e., if a cell line possessed a functional mutation
of anygenemember of thepathway then that cell linewasconsid-
eredmutated in that pathway. This resulted in a set of 15 pathway
groupings (Table S1M) that were perturbed in at least seven tu-
mor cell lines. Associating pathway mutations with KGDs was
then performed in the same way as for individual genes using
the MP test approach. This resulted in the identification of an
additional 338 dependencies across all histotypes (Table S1N)
and 748 histotype-specific dependencies (Table S1O).
As with individual driver genes, we found that the mutation
of pathways was often associated with dependencies that
were densely connected on the STRING functional interaction
network. Indeed, using the dependencies identified across all
histotypes, we found that nine of the 15 pathways (HR, PRC2,
PI3K signaling, Cell Cycle Oncogenes, Cell Cycle Merged, TOR
Signaling, MAPK Signaling, TGF B Signaling, and RAS/RAF
Signaling) were associated with dependencies that were more
functionally connected than would be expected by chance.s
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Figure 5. Pathway Mutations Associated with KGDs
(A) Heatmap showing increased dependency on TWF2 in cell lines with loss-of-function mutations in members of the SWI-SNF complex.
(B) Heatmap showing increased dependency on UCK2 in ovarian cancer cell lines with loss-of-function mutations in members of the SWI-SNF complex.
(C) Heatmap showing increased dependency on DAPK1 in esophageal cancer cell lines with loss-of-function mutations in members of the SWI-SNF complex.
(D) Heatmap showing increased dependency upon CDK6 in cell lines bearing mutations in KRAS, HRAS, NRAS, or BRAF.
See also Figure S5 and Tables S1M–S1O.This suggested thatmutation of one pathwaymay induce depen-
dency on a second pathway, consistent with observations from
yeast where it has been shown genetic dependencies can often
be best explained as occurring between pairs of pathways (Kel-
ley and Ideker, 2005). The dependency graphs associated with
each pathway are presented in Figure S5.
In some instances, the association between a pathway and ki-
nase siRNA had a predictive value no greater than the associa-
tion with an individual member of the pathway. For example,
alteration in the mTOR signaling pathway (mutation in TSC1
OR TSC2 OR STK11) was associated with an increased depen-
dency upon the signal recognition particle SRP72 gene (rho =
0.40), but mutation of STK11 alone better explained the relative
sensitivity of mutant and non-mutant cell lines in this regard
(rho =0.44). We therefore filtered these associations to identify
175 across-histotype (Table S1N) and 608 histotype-specific
pathway dependencies where the pathway was a better predic-
tor of dependency than any one individual gene (Table S1O). One
example of a pathway dependency involved loss-of-functionCellmutations in the genes encoding components of the SWI/SNF
complex, mutated in 20% of all human cancers. By grouping
all tumor cell lines that had a loss-of-function mutation or
homozygous deletion of any member of the SWI/SNF complex
(including the genes ARID1A, SMARCA1, SMARCA4, ARID2,
ARID1B, and PBRM1) and then carrying out MP tests on the
siRNA data as before, we identified ten KGDs including TWF2
(Figure 5A), a gene encoding a protein that affects the stability
of the actin cytoskeleton through interaction with G-actin (Pivo-
varova et al., 2013). Further dependencies were identified for this
complex within specific histotypes including the uridine-cytidine
kinase gene UCK2 (Van Rompay et al., 2001) in ovarian cancer
models (Figure 5B) and the death-associated protein kinase
gene DAPK1 in esophageal cancer models (Figure 5C).
We also investigated MAPK gene alterations (including RAS
gene or BRAF mutations) as a pathway and found a CDK6 KGD
(Figure 5D). The dependency of KRAS mutant tumor cell lines
upon CDK6was readily apparent (rho =0.38), but was stronger
when KRAS, HRAS, NRAS, or BRAF mutant tumor cell lineReports 14, 2490–2501, March 15, 2016 ª2016 The Authors 2497
modelswere combined as agroup (rho=0.43). CDKs, including
CDK6, have been identified by a number of groups as putative
non-oncogene addictions for KRAS mutant cancers (Barbie
et al., 2009; Puyol et al., 2010). Our results suggest that CDK6
might be a non-oncogene addiction not just for KRAS mutant
models, but also for cell lines with any one of a variety of MAPK
activating mutations (NRAS, HRAS, and BRAF). We tested this
hypothesis using published drug screening results for a CDK4/
6 inhibitor (PD0332991) in 628 cell lines (Garnett et al., 2012)
and found a significant association between mutation of the
MAPK pathway and sensitivity to this inhibitor (p = 2.5 3 103,
Mann-Whitney U [MW U]-test). None of the individual members
of this pathway showed as strong an association with this inhib-
itor (KRAS p = 1.93 101, HRAS p = 5.83 102, NRAS p = 1.73
102, BRAF p = 2.8 3 102, and MW U-test).
DISCUSSION
A key challenge in the study of cancer biology is to understand
how driver mutations alter the cellular state to promote tumor
progression and how these altered states may be exploited in
the development of targeted therapeutic approaches to the
disease (Yaffe, 2013). Here, we have used siRNA screening to
quantitatively estimate the kinase requirements of tumor cell
lines in an attempt to understand better the genetic depen-
dencies present. By integrating our siRNA data with molecular
and histotype classifications, we have identified KGDs associ-
ated with particular cancer histologies or the presence of partic-
ular driver gene mutations. By integrating the KGD data with
additional sources of annotation, such as protein-protein inter-
action data, we have tried to exemplify how testable hypotheses
can be framed to explain the associations between a biomarker,
such as a driver gene mutation, and a kinase dependency. Our
aim in providing this data and illustrating its potential utility is
to present starting points for further work.
As with any large functional data set, it is important to point out
where elements of the technology usedmight influence the inter-
pretation of the data. In general, siRNA mediated gene silencing
is transient, when compared to, for example, short hairpin (sh)
RNAmediated RNAi. With this in mind, we used a relatively short
cell culture period between transfection and cell viability assess-
ment (a 4 to 7 day period). Nevertheless, we cannot predict
whether longer-term cell culture or longer-term gene silencing
might result in a somewhat different profile of genetic depen-
dencies. Furthermore, we used an ATP-based assay of cell
viability in the screens. Some modes of cell inhibition exist that
might have been missed using this method. As with any high-
throughput technique, siRNA screens also have inherent false-
positive and false-negative effects. Addressing false positives
is especially important given the well-documented off-target
effects associated with RNAi reagents (Jackson and Linsley,
2010). Consequently, we recommend that subsequent work
that builds on the dependencies we have identified encapsulates
some form of orthogonal validation. Individual siRNAs designed
to target a gene (as we have shown in the case of DYRK1A de-
pendency in RB1 null cell lines) or small molecule inhibitors (as
we have shown for the FGFR sensitivity of osteosarcoma cell
lines) might be used as a form of validation. Alternatively,2498 Cell Reports 14, 2490–2501, March 15, 2016 ª2016 The Authormethods such as CRISPR-Cas9 mediated gene targeting
(Sander and Joung, 2014) might be appropriate. We also note
that like all genetic screen data sets, the negative predictive
value of our data (i.e., the prediction that a particular genetic
dependency does not exist) might be somewhat limited, given
the transient and sometimes incomplete nature of gene silencing
by siRNA.
In carrying out functional screens in cancer cell lines, we have
tried to use some of the lessons learned from studies in model
organisms to aid the interpretation of our identified depen-
dencies. For example, integrating protein-protein interaction
data with functional data (Figure 5) was an approach pioneered
in the study of yeast genetic interaction screens (Beyer et al.,
2007; Kelley and Ideker, 2005). Here, we have integrated this
type of data to help frame testable hypotheses relating to the
observed dependencies. A more sophisticated level of protein-
protein interaction data for human tumor cell lines (Krogan
et al., 2015) will undoubtedly enhance our ability to understand
genetic dependencies. Similarly the availability of phosphopro-
teomic data for the cell lines in our panel may facilitate a more
mechanistic reconstruction of the signaling networks active
in each cell line. A number of approaches (e.g., So et al., 2015;
Terfve and Saez-Rodriguez, 2012) have been developed to inte-
grate siRNA or small molecule perturbations with time-course
phosphoproteomics data sets to reconstruct signaling networks.
Currently phosphoproteomic data for cancer cell line panels are
relatively limited (e.g., Casado et al., 2013; Creixell et al., 2015),
but as the overlap of cell lines covered by these phosphoproteo-
mic resources and our siRNA resource increases there will
be opportunities for the development of further integrative
modeling approaches. Similarly, the increased availability of pro-
tein expression data sets (e.g., Lawrence et al., 2015; Moghad-
das Gholami et al., 2013) may provide further opportunities for
the development of additional integrative approaches.
Finally, to make our resource as useful to the community as
possible, we have made all of the data described in this
manuscript available (https://cansar.icr.ac.uk/), alongside the
computational scripts used to integrate data (https://github.
com/GeneFunctionTeam/cell_line_functional_annotation).EXPERIMENTAL PROCEDURES
siRNA and Small Molecule Screening
Cell lines were transfected with a plate-arrayed siRNA library targeting 714 ki-
nases and kinase-related genes (Dharmacon SMARTpools). Positive control
(siPLK1) and multiple negative controls (siCON1 and siCON2; Dharmacon,
catalog numbers D-001210-01-20 and D-001206-14-20) and AllStar (QIAGEN,
catalognumber1027281)were includedoneveryplate. 20breastcancermodels
were screened in a 96-well-plate format while the remaining cell lines were
screened in a 384-well-plate format (Table S1A). All screens were performed in
triplicate. Cell viabilitywas estimated as cells reached 70%confluency (normally
4–7daysafter transfection) usingaCellTiter-Gloassay (Promega).Dataprocess-
ing and quality control was performed using the cellHTS2 R package (Boutros
et al., 2006). Further details, including small molecule sensitivity testing, are pro-
vided in the Supplemental Information.
Association Testing
To identify associations between specific features (histotype or driver gene
mutation) and sensitivity to specific siRNAs, a one-sided MP test was used.
For each siRNA, we compared the observed difference between the medians
Z score of the interest group and the median Z score of the ‘‘other’’ group to
that expected based on random permutation. There were one million random
samples that were created with the same sample sizes as the interest and
other groups and the difference in the medians of the two groups calculated,
allowing an empirically determined p value to be calculated. Correction for
multiple testing was performed using the Benjamini and Hochberg FDR (Ben-
jamini and Hochberg, 1995) and only those at an FDR of 50% are reported. For
all small molecule association tests, we used a one-sided MW U test on area
under the dose response curve values.
Data Access
All siRNA Z score data can be found in Table S1B and also at https://cansar.icr.
ac.uk/.
Data Integration
Data fromHINT (Das and Yu, 2012), BioGRID version 3.4.128 (Chatr-Aryamon-
tri et al., 2015), and KEA protein- protein interaction databases were used
(Lachmann and Ma’ayan, 2009). Kinase-substrate interactions were obtained
from KEA (Lachmann and Ma’ayan, 2009), PhosphoSitePlus (Hornbeck et al.,
2015) and (Cheng et al., 2014). High confidence (combined score >0.7) func-
tional interactions were obtained from the STRING database (Version 9.1;
Franceschini et al., 2013). Gene expression relationships were obtained from
Pathway Commons (Cerami et al., 2011). The shortest_path function in
NetworkX (Hagberg et al., 2008) was also used. Further details are provided
in the Supplemental Information.
ACCESSION NUMBERS
The accession number for the exome sequencing data of 11 ovarian cancer
cell lines reported in this study is ENA: PRJEB9639.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.02.023.
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